Human Vaccines & Immunotherapeutics (Mar 2019)

Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

  • Matt Wasserman,
  • Maria Gabriela Palacios,
  • Ana Gabriela Grajales,
  • Michele Wilson,
  • Cheryl McDade,
  • Raymond Farkouh

DOI
https://doi.org/10.1080/21645515.2018.1558691
Journal volume & issue
Vol. 15, no. 3
pp. 572 – 574

Abstract

Read online

In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional information and clarifies potential misinterpretations.

Keywords